Evidence map›Paper›PMID 25891802›Full record

ArticleThe Biochemical journal2015

Suppression of interferon β gene transcription by inhibitors of bromodomain and extra-terminal (BET) family members.

Nazma Malik, Stefan Vollmer, Sambit Kumar Nanda, Marta Lopez-Pelaez, Alan Prescott, Nathanael Gray, Philip Cohen

Open access · hybridAbstract read
In one paragraph

Article in The Biochemical journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. MAPK/MAK/MRK overlapping kinase (MOK) controls microglial inflammatory/type-I IFN responses via Brd4 and is involved in ALS.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. The BET family in immunity and disease.Signal transduction and targeted therapy · 2021
    Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Nazma MalikMRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, Dow Street, University of Dundee, Dundee DD1 5EH, Scotland, U.K.
Stefan VollmerMRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, Dow Street, University of Dundee, Dundee DD1 5EH, Scotland, U.K.
Sambit Kumar NandaMRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, Dow Street, University of Dundee, Dundee DD1 5EH, Scotland, U.K.
Marta Lopez-PelaezMRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, Dow Street, University of Dundee, Dundee DD1 5EH, Scotland, U.K.
Alan PrescottDivision of Cell Signalling and Immunology, College of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland, U.K.
Nathanael GrayDana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, U.S.A.
Philip CohenMRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, Dow Street, University of Dundee, Dundee DD1 5EH, Scotland, U.K. p.cohen@dundee.ac.uk.
MRC Protein Phosphorylation and Ubiquitylation Unit · GBDana-Farber Cancer Institute · USUniversity of Dundee · GB

Funding

Medical Research Council MC_UU_12016/11Medical Research Council MR/K000985/1Wellcome Trust 100294
6 · The paper itself

Abstract

PLK (Polo-like kinase) inhibitors, such as BI-2536, have been reported to suppress IFNB (encoding IFNβ, interferon β) gene transcription induced by ligands that activate TLR3 (Toll-like receptor 3) and TLR4. In the present study, we found that BI-2536 is likely to exert this effect by preventing the interaction of the transcription factors IRF3 (interferon-regulatory factor 3) and c-Jun with the IFNB promoter, but without affecting the TBK1 {TANK [TRAF (tumour-necrosis-factor-receptor-associated factor)-associated nuclear factor κB activator]-binding kinase 1}-catalysed phosphorylation of IRF3 at Ser³⁹⁶, the dimerization and nuclear translocation of IRF3 or the phosphorylation of c-Jun and ATF2 (activating transcription factor 2). Although BI-2536 inhibits few other kinases tested, it interacts with BET (bromodomain and extra-terminal) family members and displaces them from acetylated lysine residues on histones. We found that BET inhibitors that do not inhibit PLKs phenocopied the effect of BI-2536 on IFNB gene transcription. Similarly, BET inhibitors blocked the interaction of IRF5 with the IFNB promoter and the secretion of IFNβ induced by TLR7 or TLR9 ligands in the human plasmacytoid dendritic cell line GEN2.2, but without affecting the nuclear translocation of IRF5. We found that the BET family member BRD4 (bromodomain-containing protein 4) was associated with the IFNB promoter and that this interaction was enhanced by TLR3- or TLR4-ligation and prevented by BI-2536 and other BET inhibitors. Our results establish that BET family members are essential for TLR-stimulated IFNB gene transcription by permitting transcription factors to interact with the IFNB promoter. They also show that the interaction of the IFNB promoter with BRD4 is regulated by TLR ligation and that BI-2536 is likely to suppress IFNB gene transcription by targeting BET family members.

Indexed as

Transcription, GeneticAnimalsAntimitotic AgentsBromodomain Containing ProteinsCell Cycle ProteinsCell Line, TransformedDendritic CellsHumansInterferon-betaInterferon Regulatory Factor-3LigandsMacrophagesMiceNuclear ProteinsPromoter Regions, GeneticProtein IsoformsAntimitotic AgentsBI 2536BRD4 protein, humanBrd4 protein, mouseBromodomain Containing ProteinsCell Cycle ProteinsInterferon-betaInterferon Regulatory Factor-3LigandsNuclear ProteinsProtein IsoformsProto-Oncogene Proteins c-junPteridinesToll-Like Receptor 7Toll-Like Receptor 9Transcription FactorsBI-2536bromodomain and extra-terminalhistoneinterferonPolo-like kinaseToll-like receptor

Identifiers

PMID25891802
PMCPMC4613535
OpenAlexW2093635317

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.